Home
|
Help
|
Contact
Sign in
WPRIM Management System>
DCMS
>
Osteoporosis and Sarcopenia
>
2017
>
3
>
1
Volume:
3
Issue:
1
1. Denosumab for the treatment of osteoporosis.
Page:8—17
2. An update of the Malaysian Clinical Guidance on the management of glucocorticoid-induced osteoporosis, 2015.
Page:1—7
3. Response to the Editor.
Page:60—61
4. Letter to the Editor.
Page:59—59
5. Associations between serum 25-hydroxyvitamin D3 level and skeletal muscle mass and lower limb muscle strength in Japanese middle-aged subjects.
Page:53—58
6. Bone turnover rate and bone formation/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change.
Page:45—52
7. Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study.
Page:37—44
8. Favorable effects of skeletal muscle on bone are distinguished according to gender and skeletal sites.
Page:32—36
9. Osteoporosis prevention and osteoporosis exercise in community-based public health programs.
Page:18—31